Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Rosenfeld, Nitzan"'
Autor:
Nygård L; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Ahlborn LB; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Persson GF; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Chandrananda D; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, England, United Kingdom., Langer JW; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark., Fischer BM; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; PET Centre, School of Biomedical Engineering and Imaging Sciences, Kings College London, St Thomas' Hospital, London, England, United Kingdom., Langer SW; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Gabrielaite M; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Kjær A; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark., Rosenfeld N; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, England, United Kingdom., Mouliere F; Department of Pathology, Cancer Centre Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Østrup O; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Vogelius IR; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Bentzen SM; Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, University of Maryland Greenebaum Comprehensive Cancer Center, and University of Maryland School of Medicine, Baltimore, MD, United States of America.
Publikováno v:
PloS one [PLoS One] 2020 Apr 28; Vol. 15 (4), pp. e0231884. Date of Electronic Publication: 2020 Apr 28 (Print Publication: 2020).
Autor:
Tsui DWY; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Major Center - Cambridge, Cambridge, UK., Murtaza M; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Major Center - Cambridge, Cambridge, UK.; Department of Oncology, University of Cambridge, Cambridge, UK., Wong ASC; Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore., Rueda OM; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Major Center - Cambridge, Cambridge, UK., Smith CG; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Major Center - Cambridge, Cambridge, UK., Chandrananda D; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Major Center - Cambridge, Cambridge, UK., Soo RA; Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore.; Cancer Science Institute, Centre for Translational Medicine, National University of Singapore, Singapore, Singapore., Lim HL; Parkway Cancer Center, Singapore, Singapore., Goh BC; Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore.; Cancer Science Institute, Centre for Translational Medicine, National University of Singapore, Singapore, Singapore., Caldas C; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Major Center - Cambridge, Cambridge, UK.; Department of Oncology, University of Cambridge, Cambridge, UK.; Department of Oncology, Addenbrooke's Hospital, Cambridge University Health Partners, Cambridge, UK., Forshew T; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Major Center - Cambridge, Cambridge, UK., Gale D; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Major Center - Cambridge, Cambridge, UK., Liu W; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Major Center - Cambridge, Cambridge, UK., Morris J; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Major Center - Cambridge, Cambridge, UK., Marass F; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Cancer Research UK Major Center - Cambridge, Cambridge, UK., Eisen T; Department of Oncology, University of Cambridge, Cambridge, UK.; Department of Oncology, Addenbrooke's Hospital, Cambridge University Health Partners, Cambridge, UK.; Oncology Early Clinical Development, AstraZeneca, Cambridge, UK., Chin TM; Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore csictm@nus.edu.sg nitzan.rosenfeld@cruk.cam.ac.uk.; Cancer Science Institute, Centre for Translational Medicine, National University of Singapore, Singapore, Singapore.; Raffles Cancer Centre, Raffles Hospital, Singapore, Singapore., Rosenfeld N; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK csictm@nus.edu.sg nitzan.rosenfeld@cruk.cam.ac.uk.; Cancer Research UK Major Center - Cambridge, Cambridge, UK.
Publikováno v:
EMBO molecular medicine [EMBO Mol Med] 2018 Jun; Vol. 10 (6).
Autor:
Murtaza M; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.; Department of Oncology, University of Cambridge, Cambridge CB2 0RE, UK.; Center for Noninvasive Diagnostics, Translational Genomics Research Institute, Phoenix, Arizona 85004, USA.; Mayo Clinic Center for Individualized Medicine, Scottsdale, Arizona 85259, USA., Dawson SJ; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.; Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital National Health Service Foundation Trust and National Institute for Health Research Cambridge Biomedical Research Centre, and the Cambridge Experimental Cancer Medicine Centre, Cambridge CB2 0QQ, UK.; Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia., Pogrebniak K; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.; Department of Oncology, University of Cambridge, Cambridge CB2 0RE, UK., Rueda OM; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.; Department of Oncology, University of Cambridge, Cambridge CB2 0RE, UK., Provenzano E; Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital National Health Service Foundation Trust and National Institute for Health Research Cambridge Biomedical Research Centre, and the Cambridge Experimental Cancer Medicine Centre, Cambridge CB2 0QQ, UK.; Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge CB2 0QQ, UK., Grant J; Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge CB2 0QQ, UK., Chin SF; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.; Department of Oncology, University of Cambridge, Cambridge CB2 0RE, UK., Tsui DWY; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK., Marass F; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.; Department of Oncology, University of Cambridge, Cambridge CB2 0RE, UK., Gale D; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK., Ali HR; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.; Department of Oncology, University of Cambridge, Cambridge CB2 0RE, UK.; Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital National Health Service Foundation Trust and National Institute for Health Research Cambridge Biomedical Research Centre, and the Cambridge Experimental Cancer Medicine Centre, Cambridge CB2 0QQ, UK.; Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge CB2 0QQ, UK., Shah P; Center for Noninvasive Diagnostics, Translational Genomics Research Institute, Phoenix, Arizona 85004, USA., Contente-Cuomo T; Center for Noninvasive Diagnostics, Translational Genomics Research Institute, Phoenix, Arizona 85004, USA., Farahani H; BC Cancer Research Centre, Vancouver, British Columbia, Canada V5Z 1L3., Shumansky K; BC Cancer Research Centre, Vancouver, British Columbia, Canada V5Z 1L3., Kingsbury Z; Illumina, Inc., Chesterford Research Park, Little Chesterford CB10 1XL, UK., Humphray S; Illumina, Inc., Chesterford Research Park, Little Chesterford CB10 1XL, UK., Bentley D; Illumina, Inc., Chesterford Research Park, Little Chesterford CB10 1XL, UK., Shah SP; BC Cancer Research Centre, Vancouver, British Columbia, Canada V5Z 1L3., Wallis M; Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital National Health Service Foundation Trust and National Institute for Health Research Cambridge Biomedical Research Centre, and the Cambridge Experimental Cancer Medicine Centre, Cambridge CB2 0QQ, UK.; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge CB2 0QQ, UK., Rosenfeld N; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.; Department of Oncology, University of Cambridge, Cambridge CB2 0RE, UK., Caldas C; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK.; Department of Oncology, University of Cambridge, Cambridge CB2 0RE, UK.; Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospital National Health Service Foundation Trust and National Institute for Health Research Cambridge Biomedical Research Centre, and the Cambridge Experimental Cancer Medicine Centre, Cambridge CB2 0QQ, UK.
Publikováno v:
Nature communications [Nat Commun] 2015 Nov 04; Vol. 6, pp. 8760. Date of Electronic Publication: 2015 Nov 04.
Autor:
Voon PJ; Corresponding Author: Tan Min Chin, Department of Hematology-Oncology, National University Cancer Institute, National University Health System, 5 Lower Kent Ridge Road, Tower Block Level 7, Singapore 119074. Tan_Min_CHIN@nuhs.edu.sg., Tsui DW, Rosenfeld N, Chin TM
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2013 Nov; Vol. 12 (11), pp. 2614-5. Date of Electronic Publication: 2013 Aug 22.
Autor:
Lebanony D; Rosetta Genomics Ltd, 10 Plaut St, Rehovot 76706, Israel. ranit_ah@rosettagenomics.com, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2009 Apr 20; Vol. 27 (12), pp. 2030-7. Date of Electronic Publication: 2009 Mar 09.
Autor:
Tsui, Dana Wai Yi, Murtaza, Muhammed, Wong, Alvin Seng Cheong, Rueda, Oscar M, Smith, Christopher G, Chandrananda, Dineika, Soo, Ross A, Lim, Hong Liang, Goh, Boon Cher, Caldas, Carlos, Forshew, Tim, Gale, Davina, Liu, Wei, Morris, James, Marass, Francesco, Eisen, Tim, Chin, Tan Min, Rosenfeld, Nitzan
Publikováno v:
EMBO Molecular Medicine, 10 (6)
Tumour heterogeneity leads to the development of multiple resistance mechanisms during targeted therapies. Identifying the dominant driver(s) is critical for treatment decision. We studied the relative dynamics of multiple oncogenic drivers in longit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19c2271a081f331b4eb008699065198e
https://www.repository.cam.ac.uk/handle/1810/278861
https://www.repository.cam.ac.uk/handle/1810/278861
Autor:
Remon, J, Caramella, C, Jovelet, C, Lacroix, L, Lawson, Andrew, Smalley, S, Howarth, K, Gale, Davina, Green, E, Plagnol, V, Rosenfeld, Nitzan, Planchard, D, Bluthgen, MV, Gazzah, A, Pannet, C, Nicotra, C, Auclin, E, Soria, JC, Besse, B
Background: Approximately 50% of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) will acquire resistance by the T790M mutation. Osimertinib is the standard
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::218c824277d1fafe61b827249ca91669